C12N 2740/15041
Use of virus, viral particle or viral elements as a vector
C12N2740/15041 (Use of virus, viral particle or viral elements as a vector) appears on 841 US grants and 2,279 published applications in this corpus.
Search patents in C12N- Granted patents
- 841
- Published applications
- 2,279
- Assignees
- 953
- Inventors
- 4,695
- Latest grant
- 6 Oct 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1990 | 1 | 0 |
| 1991 | 0 | 0 |
| 1992 | 1 | 0 |
| 1993 | 0 | 0 |
| 1994 | 0 | 0 |
| 1995 | 0 | 0 |
| 1996 | 2 | 0 |
| 1997 | 3 | 0 |
| 1998 | 3 | 0 |
| 1999 | 3 | 0 |
| 2000 | 2 | 0 |
| 2001 | 7 | 3 |
| 2002 | 2 | 7 |
| 2003 | 2 | 29 |
| 2004 | 7 | 17 |
| 2005 | 4 | 22 |
| 2006 | 9 | 32 |
| 2007 | 9 | 15 |
| 2008 | 6 | 20 |
| 2009 | 12 | 26 |
| 2010 | 10 | 31 |
| 2011 | 11 | 36 |
| 2012 | 15 | 19 |
| 2013 | 15 | 31 |
| 2014 | 28 | 44 |
| 2015 | 29 | 61 |
| 2016 | 44 | 82 |
| 2017 | 33 | 89 |
| 2018 | 44 | 89 |
| 2019 | 56 | 115 |
| 2020 | 66 | 128 |
| 2021 | 47 | 132 |
| 2022 | 64 | 200 |
| 2023 | 73 | 191 |
| 2024 | 75 | 320 |
| 2025 | 80 | 302 |
| 2026 | 78 | 238 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Subgroups
Granted patents
- C12N 2740/15043Viral genome or elements thereof as genetic vectorIndexing code734
- C12N 2740/15045Special targeting system for viral vectorsIndexing code72
- C12N 2740/15042Virus or viral particle as vehicleIndexing code26
- C12N 2740/15044Chimeric viral vector comprising heterologous viral elements for production of another viralIndexing code3
Recent patents
- BCMA chimeric antigen receptors6 Oct 2026US 12,752,006 B2Regeneron Pharmaceuticals, Inc.
- Polypeptide exhibiting fluorescent properties and use for same6 Oct 2026US 12,753,213 B2Riken
- Composition for inducing direct cross differentiation of somatic cell into motor neuron, and method for using same6 Oct 2026US 12,753,385 B2Unist (Ulsan National Institute of Science and Technology)
- Construction of chimeric antigen receptor targeting CD20 antigen and activity identification of engineered T cells thereof29 Sep 2026US 12,747,279 B2Abelzeta Inc.
- Compositions useful in treatment of ornithine transcarbamylase (OTC) deficiency29 Sep 2026US 12,747,429 B2The Trustees of the University of Pennsylvania
- Materials and methods for increasing immune responses within a mammal8 Oct 2026US 2026/0306668 A1Mayo Foundation for Medical Education and Research
- Hybrid transient transfection using transposase for high yield product production8 Oct 2026US 2026/0308275 A1Lonza Biologics PLC
- Genetically engineered cd4 t-cells for in situ synthesis of proteins8 Oct 2026US 2026/0308515 A1SRI International
- Methods of enhancing or modifying nk cells8 Oct 2026US 2026/0308525 A1Zelluna Immunotherapy AS
- Anti-cancer treatments and methods of use thereof8 Oct 2026US 2026/0308535 A1
Most cited
By later US patents
- Engineering and optimization of systems, methods and compositions for sequence manipulation with functional domains568US 8,993,233 B2Massachusetts Institute of Technology · 2015
- Engineering and optimization of systems, methods and compositions for sequence manipulation with functional domains475US 8,999,641 B2Maassachusetts Institute of Technology · 2015
- Methods for treatment of cancer368US 8,906,682 B2The Trustees of the University of Pennsylvania · 2014
- Compositions for treatment of cancer277US 8,911,993 B2The Trustees of the University of Pennsylvania · 2014
- Methods for treatment of cancer216US 8,916,381 B1The Trustees of the University of Pennyslvania · 2014